## Supplemental Information

## Enhancing Chemoradiation of Colorectal Cancer Through Targeted

Delivery of Raltitrexed by Hyaluronic Acid Coated Nanoparticles

Justin G. Rosch<sup>a</sup>, Madeleine R. Landry<sup>a</sup>, Charles R. Thomas, Jr.<sup>b</sup>, and Conroy Sun<sup>a,b,\*</sup>

<sup>a</sup> Department of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, Portland, OR 97201, USA

<sup>b</sup> Department of Radiation Medicine, School of Medicine, Oregon Health & Science University, Portland, OR 97239, USA

\*Corresponding Author:

Conroy Sun, Ph.D.

Department of Pharmaceutical Sciences

Oregon State University

2730 SW Moody Ave

Portland, OR 97201-5041, USA

Email: sunc@ohsu.edu

Phone: 503-346-4699



Figure S1. TEM of bare CML nanoparticles prior to layer-by-layer deposition.



**Figure S2**. Fluorescence microscopy images of no treatment and CML-PLA-HA treated wells after 24 h exposure. The no treatment well is the same as presented in **Figure 3**. The hyaluronic acid only nanoparticles showed similar fluorescence to the HARPs.



Figure S3. 24, 48, and 72 h viability curves for raltitrexed and HARPs.



**Figure S4**. Stacked histograms showing the changing fluorescent signal with different treatments (γH2AX assay).